Hodgkin's Lymphoma
Hodgkin's Lymphoma
Hodgkin's Lymphoma
Hodgkins Lymphoma
Malignancy of lymphoid tissue
Unknown aetiology
Highly associated with Epstein-Barr Virus
Boys > Girls
Bimodal distribution
Peaks : 1) Adolescent/ young adult years
(Rare below 5 years of age)
2) After 50 years old
Pathophysiology
Clinical manifestations
Painless ,firm lymphadenopathy
Confined to one or two lymph nodes areas
(supraclavicular and cervical lymph nodes
Mediastinal lymphadenopathy cough, shortness
of breadth, chest pain RISK of respiratory failure
May also cause superior vena cava syndrome
(dyspnoea, facial swelling, head fullness,cough,
arm swelling,chest pain, dysphagia, orthopnea,
distorted vision, hoarseness, stridor,headache,
nasal stuffiness, nausea, pleural effusions, and
light-headedness.)
Pathologic
confirmation: ReedSternberg cells
Binucleated or
multinucleated
giant cells. Bilobed
nucleus with 2 large
nucleoli that
produces the
characteristic "owls
eye" appearance.
The typical RSC is
characterized by
CD30 positivity,
absence of J chains
Histopathology subtypes:
1)
2)
3)
4)
Differential diagnosis
Leukemia
Rhabdomysarcoma
Nasopharyngeal carcinoma
Germ cell tumour
Thymomas
Infectious mononucleosis
Branchial cleft, thyroglossal duct cysts
Cat scratch disease
Toxoplasmosis
Tinea capitis
Treatment
Chemotherapy (highly sensitive)
- Cyclophosphamide, vincristine,
procarbazine, doxorubicin,
bleomycin, vinblastine, prednisone,
etoposide
Low dose radiation therapy
Complication
From treatment:
Short term:
- Immunosuppresion: nausea, vomiting,
alopecia
Late adverse effects:
- Second malignant neoplasm( AML, thyroid
malignancies, breast cancer)
- Hypothyroid, impaired soft tissue and bone
growth, cardiac dysfunction, pulmonary
fibrosis
Prognosis
Excellent
90% - 5 years overall survival rate
Survival in developing countries may
be lower, depending on availability of
care and medications, distance to
the treating centers, and number of
patients who abandon therapy before
completion.